PANCREATIC ADENOCARCINOMA
Clinical trials for PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial targets Hard-to-Treat pancreatic cancer in patients with BRCA mutations
Disease control Not yet recruitingThis study tests a drug called lorigerlimab in 40 adults with advanced pancreatic cancer that has a specific genetic change (BRCA1/2, PALB2, or RAD51C/D). The goal is to see if the drug can shrink tumors. Participants must have tried other treatments first. This is not a cure, bu…
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated May 16, 2026 23:53 UTC
-
New combo therapy targets tough pancreatic tumors
Disease control Not yet recruitingThis early-phase trial tests whether combining targeted radiation (SBRT) with an experimental immunotherapy called PCX12 is safe for people with locally advanced pancreatic cancer. About 24 participants who have already had chemotherapy will receive the radiation followed by inje…
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Haoming (Carl) Qiu • Aim: Disease control
Last updated May 16, 2026 23:49 UTC
-
New surgical order may boost pancreatic cancer outcomes
Disease control Not yet recruitingThis study tests whether changing the order of steps during a Whipple surgery for pancreatic head cancer can help surgeons remove the tumor more completely and lower the chance of cancer coming back. About 150 adults with operable pancreatic cancer will be randomly assigned to ei…
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug targets hard-to-treat cancers with missing gene
Disease control Not yet recruitingThis early-phase study tests a new drug called CS08399 in people with advanced solid tumors or lymphoma that have a specific genetic deletion (MTAP). The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 186 adults who have run out of …
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new combination of two drugs (L19IL2 and ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 …
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC